DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay ...

With that said, some initial peak revenue forecasts BMY shared for certain assets - $4bn for opdualag, the melanoma med, >$3bn for ulcerative colitis therapy Zeposia, and cell therapy breyanzi ...

Bristol-Myers Squibb Company BMY reported first-quarter 2025 adjusted earnings per share (EPS) of $1.80, which comfortably beat the Zacks Consensus Estimate of $1.51. In the year-ago quarter ...

Bristol-Myers Squibb Company BMY reported first-quarter 2025 adjusted earnings per share (EPS) of $1.80, which comfortably ...

The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

However, the expected decline has likely been partially offset by an increase in the sales of BMY’s growth products like Opdivo, Yervoy, Reblozyl, Breyanzi, Zeposia, Opdualag and others.

The Global Multiple Sclerosis Drugs Market achieved a valuation of $23.2 Billion in 2024 and is anticipated to exceed $53.25 Billion by 2035, reflecting a compounded annual growth rate (CAGR) of 7.85% ...